Literature DB >> 10956659

Interaction of the factor XIII activation peptide with alpha -thrombin. Crystal structure of its enzyme-substrate analog complex.

C Sadasivan1, V C Yee.   

Abstract

The serine protease thrombin proteolytically activates blood coagulation factor XIII by cleavage at residue Arg(37); factor XIII in turn cross-links fibrin molecules and gives mechanical stability to the blood clot. The 2.0-A resolution x-ray crystal structure of human alpha-thrombin bound to the factor XIII-(28-37) decapeptide has been determined. This structure reveals the detailed atomic level interactions between the factor XIII activation peptide and thrombin and provides the first high resolution view of this functionally important part of the factor XIII molecule. A comparison of this structure with the crystal structure of fibrinopeptide A complexed with thrombin highlights several important determinants of thrombin substrate interaction. First, the P1 and P2 residues must be compatible with the geometry and chemistry of the S1 and S2 specificity sites in thrombin. Second, a glycine in the P5 position is necessary for the conserved substrate conformation seen in both factor XIII-(28-37) and fibrinopeptide A. Finally, the hydrophobic residues, which occupy the aryl binding site of thrombin determine the substrate conformation further away from the catalytic residues. In the case of factor XIII-(28-37), the aryl binding site is shared by hydrophobic residues P4 (Val(34)) and P9 (Val(29)). A bulkier residue in either of these sites may alter the substrate peptide conformation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10956659     DOI: 10.1074/jbc.M006076200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

1.  Exposure of R169 controls protein C activation and autoactivation.

Authors:  Nicola Pozzi; Sergio Barranco-Medina; Zhiwei Chen; Enrico Di Cera
Journal:  Blood       Date:  2012-04-24       Impact factor: 22.113

2.  Crystal structure of thrombin bound to the uncleaved extracellular fragment of PAR1.

Authors:  Prafull S Gandhi; Zhiwei Chen; Enrico Di Cera
Journal:  J Biol Chem       Date:  2010-03-17       Impact factor: 5.157

3.  Effects of introducing fibrinogen Aalpha character into the factor XIII activation peptide segment.

Authors:  Madhavi A Jadhav; Giulia Isetti; Toni A Trumbo; Muriel C Maurer
Journal:  Biochemistry       Date:  2010-04-06       Impact factor: 3.162

4.  Structural basis of thrombin-mediated factor V activation: the Glu666-Glu672 sequence is critical for processing at the heavy chain-B domain junction.

Authors:  María Ángeles Corral-Rodríguez; Paul E Bock; Erick Hernández-Carvajal; Ricardo Gutiérrez-Gallego; Pablo Fuentes-Prior
Journal:  Blood       Date:  2011-05-09       Impact factor: 22.113

5.  Design of Factor XIII V34X activation peptides to control ability to interact with thrombin mutants.

Authors:  Madhavi A Jadhav; R Cory Lucas; Whitney N Goldsberry; Muriel C Maurer
Journal:  Biochim Biophys Acta       Date:  2011-07-21

6.  Engineering thrombin for selective specificity toward protein C and PAR1.

Authors:  Francesca Marino; Leslie A Pelc; Austin Vogt; Prafull S Gandhi; Enrico Di Cera
Journal:  J Biol Chem       Date:  2010-04-19       Impact factor: 5.157

7.  Screening cleavage of Factor XIII V34X Activation Peptides by thrombin mutants: A strategy for controlling fibrin architecture.

Authors:  Madhavi A Jadhav; Whitney N Goldsberry; Sara E Zink; Kelsey N Lamb; Katelyn E Simmons; Carmela M Riposo; Boris A Anokhin; Muriel C Maurer
Journal:  Biochim Biophys Acta Proteins Proteom       Date:  2017-07-04       Impact factor: 3.036

Review 8.  Thrombin domains: structure, function and interaction with platelet receptors.

Authors:  Raimondo De Cristofaro; Erica De Candia
Journal:  J Thromb Thrombolysis       Date:  2003-06       Impact factor: 2.300

Review 9.  Thrombin.

Authors:  Enrico Di Cera
Journal:  Mol Aspects Med       Date:  2008-02-01

10.  The tick-derived anticoagulant madanin is processed by thrombin and factor Xa.

Authors:  Ana C Figueiredo; Daniele de Sanctis; Pedro José Barbosa Pereira
Journal:  PLoS One       Date:  2013-08-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.